Pharmaceutical tariffs Section 232 reshaped landed cost and sourcing risk for patented products entering the United States. For procurement, quality, and logistics teams, the lasting question is how the policy works, what stays in or out of scope, and which operational habits still matter after the rules took effect. This briefing translates Proclamation 11020 and the September 2026 specialty guidance into a durable reference for supply-chain professionals.

This article is an industry briefing for operational awareness. It is not legal, customs, or tax advice. Confirm classification, valuation, and eligibility with qualified counsel and your customs broker before acting on any shipment.

What Section 232 pharmaceutical tariffs are (plain English)

Section 232 of the Trade Expansion Act of 1962 lets the U.S. President adjust imports that Commerce finds threaten to impair national security. On April 2, 2026, the President issued Proclamation 11020, published at 91 FR 18183, adjusting imports of pharmaceuticals and associated pharmaceutical ingredients under that authority.

In operational terms, the baseline is a 100 percent ad valorem duty on certain patented pharmaceuticals and associated ingredients in Annex I — unless a lower rate or carve-out applies. Timing was company-specific: Annex III companies from July 31, 2026; other companies from September 29, 2026 (12:01 a.m. eastern), per the proclamation.

Rates are layered. Proclamation 11020 also sets:

• 20 percent for products of companies with Commerce-approved (or soon-to-be-approved) onshoring plans — scheduled to rise to 100 percent on April 2, 2030 if that track still applies.
• 15 percent for products of Japan, the European Union, the Republic of Korea, and Switzerland and Liechtenstein jointly (unless a lower rate under the proclamation applies).
• Zero (through January 20, 2029) for companies that combine approved onshoring plans with Most-Favored-Nation (MFN) pharmaceutical pricing agreements with HHS, as stated in the proclamation.
• Separate UK treatment under trade commitments; Commerce later reduced the UK patented-pharma Section 232 rate to zero under the U.S.–UK pharmaceutical pricing arrangement (Federal Register notice).

Drawback remains available, and U.S.-origin pharmaceutical products are not subject to these Section 232 tariffs at this time. For ops teams, HTSUS classification, patent vs generic status, country of origin, and any company-specific agreement can change the duty line on the same SKU.

Timeline context (historical, not a countdown)

Milestone	What it established
April 2, 2026	Proclamation 11020 issued (91 FR 18183, Apr. 9, 2026)
July 31, 2026	Effective date for Annex III companies
Sept. 23, 2026	BIS specialty 0% definitions, jurisdiction list, and urgent-health-need procedures (FR Doc. 2026-19498)
Sept. 29, 2026	Broader effective window for other companies; related HTSUS technical corrections

Patented products vs generics — what is typically in or out of scope

In focus: patented finished pharmaceuticals and associated pharmaceutical ingredients (including APIs and key starting materials) on the Annex I HTSUS lines, subject to the rates and exceptions above.

Generally out of these Section 232 pharma tariffs at this time: generic pharmaceutical products and associated ingredients, including biosimilars. Proclamation 11020 (clause 5) and the September 23, 2026 BIS notice state: “At this time, Section 232 Pharmaceutical Tariffs do not apply to generic pharmaceutical products and associated ingredients.” The proclamation also directed Commerce to report within one year on whether generics might later need adjustment — so treat the carve-out as current policy, not a permanent guarantee.

September 2026 HTSUS technical corrections clarified “pharmaceutical articles” and “generic pharmaceutical articles” for Chapter 99 (including certain unpatented animal health products in the generic definition). Classification disputes still belong with your broker and counsel — especially near the patented/generic boundary.

Specialty products and the 0% path (jurisdictions + urgent health-need requests)

Clause 3(d) of Proclamation 11020 directs a zero ad valorem Section 232 rate for defined specialty categories when Commerce (consulting USTR and HHS) finds either:

1. the goods are products of a jurisdiction with a current or forthcoming trade-and-security framework agreement (as referenced in Executive Order 14346), or
2. the import meets an urgent U.S. health need.

The BIS Federal Register notice of September 23, 2026 defines those specialty categories for tariff purposes, including (summarized): drugs where all approved or licensed indications are orphan-designated; nuclear medicines; plasma-derived therapies; fertility drugs; cell and gene therapy products; antibody-drug conjugates (ADCs); medical countermeasures related to chemical, biological, radiological, and nuclear (CBRN) threats; and animal healthcare products (as defined in the notice).

Eligible jurisdictions listed in that notice (subject to future updates) include: Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, the European Union, Guatemala, India, Indonesia, Japan, Jordan, Malaysia, North Macedonia, the Republic of Korea, Switzerland and Liechtenstein, Taiwan, Thailand, the United Kingdom, and Vietnam.

For urgent-health-need determinations, companies may submit product-specific requests on an ongoing basis to pharma232@bis.doc.gov, with organization data, HTSUS, origin, importer/manufacturer details, specialty category, and a rationale. Commerce decides case by case; CBP administers the adjustment at entry. The same notice created HTSUS heading 9903.04.70 for certain covered articles solely for clinical trials, R&D, or other non-commercial use at +0% Section 232.

Do not assume a specialty label alone equals 0%. Jurisdiction, documentation, and — where needed — an approved urgent-need determination still matter.

An evergreen procurement, quality, and logistics checklist

Use this as a recurring control set, not a one-time project:

1. Classify the portfolio. Tag each SKU as patented finished good / patented API (or key starting material) vs generic/biosimilar — and keep evidence with the master data.
2. Flag specialty candidates. Mark orphan-only, nuclear, plasma, fertility, cell/gene, ADC, CBRN countermeasure, and animal-health lines that might sit on the 0% path — then verify jurisdiction or urgent-need status before modeling savings.
3. Lock supplier jurisdiction and paperwork trails. Country of origin, manufacturer identity, and commercial invoices must support the claimed treatment.
4. Ask about onshoring / MFN agreements. Where suppliers claim reduced rates under company-specific Commerce or HHS arrangements, request written confirmation of current tariff treatment.
5. Model landed-cost scenarios. Compare full 100% exposure vs jurisdiction rates vs specialty/urgent-need 0% vs generic-out-of-scope assumptions.
6. Align quality and regulatory docs when lanes change. If you rebalance origin, warehouse, or importer of record, refresh release documentation and shipping controls alongside customs planning.
7. Revisit when guidance updates. Annex corrections, jurisdiction lists, and company agreements can change — schedule periodic HTSUS and SKU-flag reviews.

Teams that treat this as living master data absorb the next Federal Register notice with less disruption.

Sourcing resilience: documentation, alternate lanes, and partner questions

Section 232 pharmaceutical tariffs reward clean classification, honest origin stories, and partners who can explain a duty line without hand-waving. Build resilience by maintaining dual documentation packs for high-duty-risk patented SKUs; mapping alternate qualified sources before a rate change hits a single lane; asking distributors how they track Chapter 99 headings and specialty eligibility; and separating “available to ship” from “eligible for claimed tariff treatment” in purchase approvals.

MedLogIl works with pharmacies, hospitals, and healthcare providers on global pharmaceutical and medical-product distribution — including documentation-aware logistics across complex lanes. For more on how we support international orders, see our services overview and ongoing industry notes on the blog. When you want to discuss sourcing resilience for a specific portfolio, you can request a quote.

Policy will keep evolving. Teams that keep classification, specialty flags, and partner questions current stay ahead of the next update — without treating every news cycle as an emergency.

Sources

1. Presidential Proclamation 11020 — Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States (Apr. 2, 2026): White House text; Federal Register 91 FR 18183 (Apr. 9, 2026).
2. BIS — Guidance and Procedures for Implementing Tariff Adjustments for Specialty Pharmaceuticals… under Proclamation 11020, Federal Register notice (published Sept. 23, 2026), FR Doc. 2026-19498.
3. Commerce notice — Reduction of Tariffs on Patented Pharmaceuticals… for Products of the United Kingdom under Proclamation 11020: Federal Register.
4. Secondary cross-check: KPMG TaxNewsFlash — BIS specialty pharmaceuticals 0% Section 232 (Sept. 21, 2026; used only to confirm public reporting of the BIS notice).